All Stories

  1. Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
  2. Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform
  3. The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform
  4. A living systematic review protocol for COVID-19 clinical trial registrations
  5. The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?
  6. Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting
  7. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
  8. Efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a protocol for systematic review and individual patient data (IPD) meta-analysis
  9. Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
  10. A pooled analysis of the duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine
  11. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis
  12. The effect of dose on the antimalarial efficacy of artesunate-mefloquine against Plasmodium falciparum malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis
  13. Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand–Myanmar Border
  14. Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study
  15. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis
  16. Malaria control in India: A national perspective in a regional and global fight to eliminate malaria
  17. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
  18. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review
  19. Complex interactions between malaria and malnutrition: a systematic literature review
  20. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
  21. Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing
  22. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
  23. Malaria and Nutritional Status Among Children With Severe Acute Malnutrition in Niger: A Prospective Cohort Study
  24. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000
  25. Molecular markers of resistance to amodiaquine plus sulfadoxine–pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger
  26. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape
  27. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review
  28. Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges
  29. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges
  30. Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
  31. The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials
  32. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
  33. Beyond open data: realising the health benefits of sharing data: Table 1
  34. Combating poor-quality anti-malarial medicines: a call to action
  35. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data
  36. A link between poor quality antimalarials and malaria drug resistance?
  37. Ethics in Medicine Quality Surveys
  38. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
  39. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
  40. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data
  41. Artemisinin resistance in Myanmar – Authors' reply
  42. Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions
  43. The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data
  44. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker
  45. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data
  46. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria
  47. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
  48. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
  49. Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
  50. Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN)
  51. International health research monitoring: exploring a scientific and a cooperative approach using participatory action research
  52. Trends in Antimalarial Drug Use in Africa
  53. Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda
  54. Surveillance of Travellers: An Additional Tool for Tracking Antimalarial Drug Resistance in Endemic Countries
  55. Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda
  56. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
  57. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferior...
  58. Made in Europe: will artemisinin resistance emerge in French Guiana?
  59. High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN)In VitroAnalysis and Reporting Tool
  60. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011
  61. Impact of malaria during pregnancy on pregnancy outcomes in a Ugandan prospective cohort with intensive malaria screening and prompt treatment
  62. Early parasitological response following artemisinin-containing regimens: a critical review of the literature
  63. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems
  64. Mapping the Aetiology of Non-Malarial Febrile Illness in Southeast Asia through a Systematic Review—Terra Incognita Impairing Treatment Policies
  65. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
  66. Chloroquine-Resistant Malaria in Travelers Returning from Haiti after 2010 Earthquake
  67. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial
  68. Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial
  69. Performance of a Histidine-Rich Protein 2 Rapid Diagnostic Test, Paracheck Pf®, for Detection of Malaria Infections in Ugandan Pregnant Women
  70. The Threat of Artemisinin-Resistant Malaria
  71. Use of Filter Paper as a Transport Medium for Laboratory Diagnosis of Cholera under Field Conditions
  72. Evaluation of Combined LED-Fluorescence Microscopy and Bleach Sedimentation for Diagnosis of Tuberculosis at Peripheral Health Service Level
  73. Transmission of Plasmodium vivax in South-Western Uganda: Report of Three Cases in Pregnant Women
  74. Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
  75. Reducing Wasting in Young Children With Preventive Supplementation: A Cohort Study in Niger
  76. Meningitis Dipstick Rapid Test: Evaluating Diagnostic Performance during an Urban Neisseria meningitidis Serogroup A Outbreak, Burkina Faso, 2007
  77. Monitoring antimalarial resistance: launching a cooperative effort
  78. Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger
  79. Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)
  80. Global resistance surveillance: ensuring antimalarial efficacy in the future
  81. Field Evaluation of Two Rapid Diagnostic Tests for Neisseria meningitidis Serogroup A during the 2006 Outbreak in Niger
  82. Prevalence, Risk Factors, and Impact on Outcome of Cytomegalovirus Replication in Serum of Cambodian HIV-Infected Patients (2004-2007)
  83. Prevalence Study of Yaws in the Democratic Republic of Congo Using the Lot Quality Assurance Sampling Method
  84. Outbreak of Hepatitis E Virus Infection in Darfur, Sudan: Effectiveness of Real-Time Reverse Transcription-PCR Analysis of Dried Blood Spots
  85. No association between human herpesvirus 6 reactivation and cryptococcosis in human immunodeficiency virus-infected patients
  86. Mortality Risk among Children Admitted in a Large-Scale Nutritional Program in Niger, 2006
  87. Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda
  88. Assessing Antimalarial Efficacy in a Time of Change to Artemisinin-Based Combination Therapies: The Role of Médecins Sans Frontières
  89. Bleach Sedimentation: An Opportunity to Optimize Smear Microscopy for Tuberculosis Diagnosis in Settings of High Prevalence of HIV
  90. Research in Complex Humanitarian Emergencies: The Médecins Sans Frontières/Epicentre Experience
  91. Treatment of severe malnutrition with 2-day intramuscular ceftriaxonevs5-day amoxicillin
  92. Bonnes Pratiques Cliniques dans les pays en développement : recommandations en termes d’application
  93. The dynamics of measles in sub-Saharan Africa
  94. World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
  95. Prevalence, Determinants of Positivity, and Clinical Utility of Cryptococcal Antigenemia in Cambodian HIV-Infected Patients
  96. Meningitis Serogroup W135 Outbreak, Burkina Faso, 2002
  97. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis
  98. Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources
  99. Unacceptably High Mortality Related to Measles Epidemics in Niger, Nigeria, and Chad
  100. Pharyngeal carriage of Neisseria meningitidis in 2–19-year-old individuals in Uganda
  101. High sensitivity and specificity of the Pastorex® latex agglutination test for Neisseria meningitidis serogroup A during a clinical trial in Niger
  102. Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention
  103. A Large Outbreak of Hepatitis E among a Displaced Population in Darfur, Sudan, 2004: The Role of Water Treatment Methods
  104. High Mortality Associated with an Outbreak of Hepatitis E among Displaced Persons in Darfur, Sudan
  105. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique☆
  106. Late vaccination reinforcement during a measles epidemic in Niamey, Niger (2003–2004)
  107. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment
  108. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
  109. Exploring the time to intervene with a reactive mass vaccination campaign in measles epidemics
  110. Validation of single real-time TaqMan® PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens
  111. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004
  112. Risk factors associated with typhoid fever in Son La province, northern Vietnam
  113. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study
  114. Effectiveness of Mass Oral Cholera Vaccination in Beira, Mozambique
  115. Case management of a multidrug-resistant Shigella dysenteriae serotype 1 outbreak in a crisis context in Sierra Leone, 1999–2000
  116. Gastro-enteritis outbreak among Nordic patients with psoriasis in a health centre in Gran Canaria, Spain: a cohort study
  117. Outbreak of Salmonella Livingstone infection in Norway and Sweden due to contaminated processed fish products
  118. Emergence of new SalmonellaEnteritidis phage types in Europe? Surveillance of infections in returning travellers
  119. Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone
  120. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development
  121. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
  122. Detection of a previously uncommon salmonella phage in tourists returning from Europe